Arbutus Biopharma Corp. (NASDAQ:ABUS) shares saw an uptick in trading volume on Tuesday . 146,061 shares traded hands during mid-day trading, an increase of 34% from the previous session’s volume of 108,732 shares.The stock last traded at $3.80 and had previously closed at $3.94.

A number of brokerages recently issued reports on ABUS. Leerink Swann reissued a “buy” rating and issued a $12.00 target price on shares of Arbutus Biopharma Corp. in a research report on Thursday, May 5th. Zacks Investment Research cut Arbutus Biopharma Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday. Wedbush reissued an “outperform” rating and issued a $20.00 target price on shares of Arbutus Biopharma Corp. in a research report on Wednesday, May 4th. Finally, Chardan Capital raised Arbutus Biopharma Corp. from a “sell” rating to a “neutral” rating and set a $3.25 target price for the company in a research report on Thursday, June 16th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Arbutus Biopharma Corp. presently has an average rating of “Hold” and a consensus price target of $9.79.

The company’s market capitalization is $207.58 million. The firm has a 50 day moving average price of $3.92 and a 200-day moving average price of $3.95.

Arbutus Biopharma Corp. (NASDAQ:ABUS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.36. Equities analysts predict that Arbutus Biopharma Corp. will post ($1.41) earnings per share for the current fiscal year.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.